



IOWA DEPARTMENT OF JUSTICE
OFFICE OF THE ATTORNEY GENERAL

MEMORANDUM

TO: The Honorable Jason Schultz, Chair, Senate Judiciary Committee
The Honorable Matt Blake, Ranking Member, Senate Judiciary Committee
The Honorable Steven Holt, Chair, House Judiciary Committee
The Honorable Ross Wilburn, Ranking Member, House Judiciary Committee

FROM: Dan Breitbarth, Assistant Attorney General

RE: 2025 False Claims Act Annual Report

DATE: July 2026

2025 False Claims Act Annual Report

This annual report concerning activity under Iowa's False Claims Act ("Act"), Iowa Code chapter 685, is submitted by the Office of the Attorney General ("Office") pursuant to 2010 Iowa Acts, chapter 1031, section 345. (Attached.)

1. There were no cases filed under the Act by the Office during the previous calendar year (2025).
2. There were 31 cases filed under the Act by qui tam plaintiffs during the previous calendar year (2025).
 - a. See Appendix 1, Tab 2A
 - b. All cases involved the Medicaid program. No other cases involved.
 - c. The Office does not know whether the qui tam plaintiffs previously filed an action in another jurisdiction.
3. See Appendix 1, Tab 3A/3B/3C

2010 Iowa Acts
Chapter 1031, Section 345

Sec. 345. ANNUAL REPORTING REQUIREMENT. On the thirtieth day after the effective date of this division of this Act, and on the anniversary of the effective date of this division of this Act each year thereafter, the attorney general shall submit to the chairpersons and ranking members of the house and senate committees on judiciary, the legislative caucus staffs, and the legislative services agency, in electronic format, a report containing all of the following information:

1. The number of cases the attorney general filed during the previous calendar year under this chapter.
2. The number of cases qui tam plaintiffs filed under this chapter during the previous calendar year, including those cases that remain under seal, and specifying all of the following for the cases:
 - a. The state or federal court in which each case was filed and the total number filed in each court.
 - b. The state program or agency involved in each case.
 - c. The number of cases filed by qui tam plaintiffs who previously filed an action based on the same or similar transaction or allegation under the federal False Claims Act or the false claims act of another state.
3. The amount recovered by the state in the form of settlement, damages, penalties, and litigation costs, if known, and specifying the following for each case.
 - a. The case number and parties for each case in which there was a recovery.
 - b. The amount of funds recovered respectively for damages, penalties, and litigation costs.
 - c. The percentage of the recovery and the amount that the state paid to any qui tam plaintiff.

2A
MFCU Cases

Number	Date Received	Location Filed
25-0001-C	01/07/2025	Northern District of California, San Francisco
25-0002-C	01/08/2025	Middle District of Florida, Orlando Division
25-0005-C	01/17/2025	Southern District of New York
25-0006-C	01/24/2025	District of Massachusetts
25-0007-C	01/27/2025	District of New Jersey
25-0015-C	02/17/2025	Northern District of Texas, Dallas Division
25-0023-C	03/13/2025	Eastern District of Pennsylvania
25-0025-C	03/14/2025	District of Massachusetts, Eastern Division
25-0032-C	04/21/2025	Southern District of New York
25-0036-C	05/07/2025	Eastern District of Pennsylvania
25-0037-C	05/07/2025	Western District of North Carolina
25-0039-C	05/13/2025	District of Oregon, Eugene Division
25-0046-C	06/10/2025	Southern District of New York
25-0049-C	06/12/2025	District of Nevada
25-0050-C	06/16/2025	Eastern District of Pennsylvania
25-0065-C	07/24/2025	Southern District of New York (formerly Northern District of Georgia, Atlanta Division)
25-0075-C	08/22/2025	Northern District of Georgia, Atlanta Division
25-0080-C	08/27/2025	District of Massachusetts
25-0081-C	08/27/2025	Eastern District of Pennsylvania
25-0082-C	08/27/2025	District of Massachusetts
25-0083-C	08/27/2025	Northern District of California, San Francisco Division
25-0084-C	09/12/2025	District of Massachusetts
25-0087-C	09/18/2025	Northern District of Georgia
25-0095-C	10/22/2025	Eastern District of Pennsylvania
25-0096-C	11/04/2025	Eastern District of Pennsylvania
25-0097-C	11/07/2025	Northern District of California, San Jose Division
25-0098-C	11/21/2025	Northern District of Georgia, Atlanta Division
25-0099-C	11/25/2025	Northern District of Ohio, Eastern Division
25-0109-C	12/18/2025	District of Minnesota
25-0110-C	12/18/2025	Northern District of Iowa, Eastern Division
25-0111-C	12/18/2025	Eastern District of Pennsylvania

3A, 3B, 3C Data

Case Number	Case Name	Parties For Each Case		Restitution - Federal Share	Restitution - State Share	Penalty - State Share	Relator - State Share	Interest - State Share
		Relator	Provider					
1:17-cv-05187-LMM	U.S., et al., ex rel. Dirk Etheridge v. Liberator Medical Holdings, Inc., et al.	Dirk Etheridge	Liberator Medical Holdings, Inc., et al.	\$19,943.69	\$10,469.41	\$11,298.60	\$4,788.96	\$523.06
4:19-cv-00315	U.S. et al. ex rel. Steven Turck v. Walgreens Boots Alliance, Inc., et al.	Steven Turck	Walgreens Boots Alliance, Inc. & Walgreens Co.	\$69,694.34	\$64,948.60	\$10,836.79	\$13,652.79	\$63.44
19-4239	U.S. et al. ex rel Valisure, LLC v. GlaxoSmithKline PLC; et al.	Valisure LLC	GlaxoSmithKline PLC and GlaxoSmithKline LLC	\$268,750.91	\$178,635.86	\$89,317.93	\$71,120.90	
16-cv-6228	U.S. et al. ex rel. Dr. Paul Bellman v. Gilead Sciences, Inc.	Dr. Paul Bellman	Gilead Sciences, Inc	\$105,718.33	\$55,967.89	\$55,967.90	\$21,267.80	\$430.74
2:19-cv-01288 JAM-JDP	U.S. et al. ex rel. Sunil Wadhwa & Ken Newton v. Admera Health; et al.	Sunil Wadhwa & Ken Newton	Admera Health; Genewiz, Inc.; Genewiz Group; Bioanalysis Diagnostic Laboratories; et al.	\$283.32	\$307.07		\$49.13	\$31.10
21-cv-6539	U.S. et al. ex rel. Patricia Frattasio v. Biohaven Pharmaceuticals, Inc., et al.	Patricia Frattasio	Biohaven Pharmaceuticals, Inc. and Biohaven Pharmaceuticals Holding Company, Ltd.	\$624,717.49	\$188,483.46	\$188,483.46	\$75,846.20	\$5,337.39
MDL No. 2724	In re Generic Pharmaceuticals Pricing Antitrust Litigation	N/A	Apotex Corp		\$76,264.87			
19-1670	U.S. et al. ex rel. Omni Healthcare v. OPKO Health	Omni Healthcare	OPKO Health, et al.	\$11.96	\$5.82	\$5.82		
2:18-01010/21-03325	U.S. et al. ex rel. Wallace, Farley, & Fuentes v. Exactech Inc. U.S. et al. ex rel. Pasquale Petrera v. Exactech, Inc., et al.	Wallace, Farley, & Fuentes/Pasquale Petrera	Exactech, Inc.	\$3,775.15	\$3,018.12			
				\$1,092,895.19	\$578,101.10	\$355,910.50	\$186,725.78	\$6,385.73